Astrazeneca (AZN) Net Income towards Common Stockholders (2009 - 2026)

Astrazeneca's Net Income towards Common Stockholders history runs 18 years deep, the most recent figure standing at $2.5 billion for Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders rose 2.33% year-over-year to $2.5 billion; the TTM figure through Jun 2026 stood at $10.9 billion (up 2.93% YoY), while the FY2025 annual figure was $10.2 billion, up 45.34% from the prior year.
• Net Income towards Common Stockholders for Q2 2026 stood at $2.5 billion, down from $3.1 billion in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $4.0 billion in Q1 2025, with the low at -$372.0 million in Q2 2022.
• The 5-year median for Net Income towards Common Stockholders is $2.1 billion (2024), against an average of $2.0 billion.
• The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders sank 131.26% in 2022, then soared 588.71% in 2023.
• Astrazeneca's Net Income towards Common Stockholders stood at $1.7 billion in 2022, then increased by 4.03% to $1.8 billion in 2023, then declined by 15.78% to $1.5 billion in 2024, then soared by 84.67% to $2.8 billion in 2025, then slipped by 9.49% to $2.5 billion in 2026.
• Business Quant data shows AZN's Net Income towards Common Stockholders at $2.5 billion in Q2 2026, $3.1 billion in Q1 2026, and $2.8 billion in Q4 2025.